Frontlight ResearchEarly access
Bladder cancer trials in Russia
1 of 2 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleSequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
- Where
- Moscow
- Age
- 18 years and over
- People
- 228
- Run by
- Blokhin's Russian Cancer Research Center
See details and how to joinNCT07747740